About Us
—
Faunded m 2018 Ania s a ioha cinca -siane iotechmo y omnay ousd n the discave an deye ment f hreakthrounh and mnvative theraneutas that adress The unmet medical needs of serous muculoskeletal diseases. Our team consists of dedicated. passionate. and experienced leaders with a proven track record in druodevelopment of musculoskeletal ciseases. The company operates in two main locations: Guanazhou. Guanadong, China. and Woodland Hils, California. USA
Core Project
Research
—
Our mission is to discover, develop and commercialize
breakthrough therapeutics that address the key unmet
medical needs of serious musculoskeletal diseases.
AGA111: Spinal Fusion
The Phase IIl.randomized.double-blind,placebocontrolled trial aims to evaluate the efficacy ancsafety of a single intervertebral local administrationof AGA111 in patients with degenerative discdisease undergoing lumbar interbody fusion.
AGA2118: Osteoporosis
AGA2118 is a frst-in-class (FIC)antibody discoveredby Angitia. Data from preclinical studies includingsafety, effcacy and pharmacokinetics in animamodels demonstrate the potential of AGA2118 for thetreatment of sever osteoporosis and other conditionsassociated with low bone mass and abnormal bonemetabolism，such as cancer-induced bone diseasesand abnormal healing of fractures.
AGA2115: Osteogenesislmperfecta
The FDA has previously granted AGA2115 an Orphan DrugDesignation (ODD) and a Rare Pediatric DiseaseDesignation(RPDD)
CAREERS
—
Angita is a global company with a diverse team.Our company culture revolves around respect and equality.We are committed to fostering employee growth and career development
Focus on Musculoskeletal Diseases
—
lt is estimated that 16 million fractures occur annually in the United States (1].and non union or poor union of fractures has always been a very challenging clinical problemBy 2040, the global aging population will double its current level,
and the phenomenon of population aging will undoubtedly bring more patients with osteoporosis and fractures
resulting in an increasingly heavy social and economic burden.
4600$
Growth financing committed
106万
Beneficiary case
60+
Dedicated Professionals
.....
Contanct us
Name
Name*
Email*
Message*